Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

DGAP-News: MorphoSys AG veröffentlicht Finanzergebnisse für das vierte Quartal und das Gesamtjahr 2021 und informiert über die aktuelle Unternehmensentwicklung
DGAP-News: MorphoSys AG veröffentlicht Finanzergebnisse für das vierte Quartal und das Gesamtjahr 2021 und informiert über die aktuelle Unternehmensentwicklung
DGAP-News: MorphoSys AG veröffentlicht Finanzergebnisse für das vierte Quartal und das Gesamtjahr 2021 und informiert über die aktuelle Unternehmensentwicklung
Southcoast Behavioral Health Expands Services and Capacity
Southcoast Behavioral Health Expands Services and Capacity


Southcoast Behavioral Health today reinforced its strong commitment to the communities it serves through the addition of a dedicated child and adolescent behavioral health program, expanding the

DGAP-News: National Comprehensive Cancer Network(R) Updates Designation of Monjuvi(R) (tafasitamab-cxix) to Preferred Regimen in its Clinical Practice Guidelines in Oncology for B-cell Lymphomas
DGAP-News: National Comprehensive Cancer Network(R) Updates Designation of Monjuvi(R) (tafasitamab-cxix) to Preferred Regimen in its Clinical Practice Guidelines in Oncology for B-cell Lymphomas
DGAP-News: National Comprehensive Cancer Network(R) Updates Designation of Monjuvi(R) (tafasitamab-cxix) to Preferred Regimen in its Clinical Practice Guidelines in Oncology for B-cell Lymphomas
DGAP-News: US-amerikanisches National Comprehensive Cancer Network(R) stuft Monjuvi(R) (Tafasitamab-cxix) in seinen Leitlinien als bevorzugte Behandlungsmethode für B-Zell-Lymphome ein
DGAP-News: US-amerikanisches National Comprehensive Cancer Network(R) stuft Monjuvi(R) (Tafasitamab-cxix) in seinen Leitlinien als bevorzugte Behandlungsmethode für B-Zell-Lymphome ein
DGAP-News: US-amerikanisches National Comprehensive Cancer Network(R) stuft Monjuvi(R) (Tafasitamab-cxix) in seinen Leitlinien als bevorzugte Behandlungsmethode für B-Zell-Lymphome ein
Premier Inc. Named One of the 2022 World’s Most Ethical Companies® by Ethisphere® for 15th Consecutive Year
Premier Inc. Named One of the 2022 World’s Most Ethical Companies® by Ethisphere® for 15th Consecutive Year


Premier, Inc. (NASDAQ: PINC), a leading healthcare improvement and technology company, has been recognized by Ethisphere®, a global leader in defining and advancing the standards of ethical

LivaNova Announces 250th Unipolar Depression Patient Implanted in RECOVER Clinical Study
LivaNova Announces 250th Unipolar Depression Patient Implanted in RECOVER Clinical Study


LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced the 250th unipolar depression patient has been implanted in the RECOVER clinical study, “A P

QIAGEN Announces 20-F Annual Report Filing for 2021 Results
QIAGEN Announces 20-F Annual Report Filing for 2021 Results


QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended

ICON plc to Webcast Analyst Day Meeting
ICON plc to Webcast Analyst Day Meeting


ICON plc, (NASDAQ:ICLR) a world-leading healthcare intelligence and clinical research organisation, today announced that it will provide a live webcast of its Analyst Day meeting which will take

DGAP-News: Einladung zu MorphoSys' Telefonkonferenz am 17. März 2022 zu den Ergebnissen des Geschäftsjahres 2021
DGAP-News: Einladung zu MorphoSys' Telefonkonferenz am 17. März 2022 zu den Ergebnissen des Geschäftsjahres 2021
DGAP-News: Einladung zu MorphoSys' Telefonkonferenz am 17. März 2022 zu den Ergebnissen des Geschäftsjahres 2021
DGAP-News: Invitation to MorphoSys' Full Year Results 2021 Conference Call on March 17, 2022
DGAP-News: Invitation to MorphoSys' Full Year Results 2021 Conference Call on March 17, 2022
DGAP-News: Invitation to MorphoSys' Full Year Results 2021 Conference Call on March 17, 2022
DGAP-Adhoc: Ad hoc: MorphoSys AG meldet nicht zahlungswirksame Wertminderung des Geschäfts- oder Firmenwertes von 231 Mio. € nach F&E Konsolidierung; entsprechende Erhöhung des operativen Konzernaufwands in 2021
DGAP-Adhoc: Ad hoc: MorphoSys AG meldet nicht zahlungswirksame Wertminderung des Geschäfts- oder Firmenwertes von 231 Mio. € nach F&E Konsolidierung; entsprechende Erhöhung des operativen Konzernaufwands in 2021
DGAP-Adhoc: Ad hoc: MorphoSys AG meldet nicht zahlungswirksame Wertminderung des Geschäfts- oder Firmenwertes von 231 Mio. € nach F&E Konsolidierung; entsprechende Erhöhung des operativen Konzernaufwands in 2021
DGAP-Adhoc: Ad hoc: MorphoSys AG reports non-cash impairment charge of € 231 million on goodwill after consolidation of research and discovery functions; corresponding increase of Group operating expenses in 2021
DGAP-Adhoc: Ad hoc: MorphoSys AG reports non-cash impairment charge of € 231 million on goodwill after consolidation of research and discovery functions; corresponding increase of Group operating expenses in 2021
DGAP-Adhoc: Ad hoc: MorphoSys AG reports non-cash impairment charge of € 231 million on goodwill after consolidation of research and discovery functions; corresponding increase of Group operating expenses in 2021
AMN Healthcare Announces CEO Susan Salka Intends to Retire by End of Year
AMN Healthcare Announces CEO Susan Salka Intends to Retire by End of Year


AMN Healthcare (NYSE: AMN), the leader and innovator in total talent solutions for healthcare organizations across the nation, today announced Susan Salka, its President and Chief Executive

Chemed Corporation to Present at the Oppenheimer 32nd Annual Healthcare Conference
Chemed Corporation to Present at the Oppenheimer 32nd Annual Healthcare Conference


Chemed Corporation (NYSE:CHE) today announced that it will deliver a virtual presentation at the Oppenheimer 32nd Annual Healthcare Conference on Wednesday, March 16, 2022, at approximately 8:40

Xencor to Present Preclinical Data from XmAb® Cytokine Programs at the American Association for Cancer Research (AACR) Annual Meeting 2022
Xencor to Present Preclinical Data from XmAb® Cytokine Programs at the American Association for Cancer Research (AACR) Annual Meeting 2022


Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will

Survey Shows Wide Earnings Gap Persists Between Male and Female Physicians in Maryland
Survey Shows Wide Earnings Gap Persists Between Male and Female Physicians in Maryland


A new survey indicates that wide pay gaps persist between male and female physicians in Maryland, and that Maryland physicians earn less on average than physicians nationwide.


This press release

Publication of definitive Interim Result for Vifor Pharma tender offer: CSL Behring AG declares offer successful
Publication of definitive Interim Result for Vifor Pharma tender offer: CSL Behring AG declares offer successful


Regulatory News:


This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220307005938/en/



AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR



CSL

Publication of provisional interim result for Vifor Pharma tender offer: Participation rate of 74 percent
Publication of provisional interim result for Vifor Pharma tender offer: Participation rate of 74 percent


Regulatory News:


This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220302006217/en/



AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR



CSL

DGAP-News: Evotec presents strategic roadmap towards precision medicine and confirms goals of Action Plan 2025 at Capital Markets Day
DGAP-News: Evotec presents strategic roadmap towards precision medicine and confirms goals of Action Plan 2025 at Capital Markets Day
DGAP-News: Evotec presents strategic roadmap towards precision medicine and confirms goals of Action Plan 2025 at Capital Markets Day
DGAP-News: Evotec präsentiert strategischen Fahrplan für Präzisionsmedizin und bestätigt Ziele des Aktionsplans 2025 auf dem Capital Markets Day
DGAP-News: Evotec präsentiert strategischen Fahrplan für Präzisionsmedizin und bestätigt Ziele des Aktionsplans 2025 auf dem Capital Markets Day
DGAP-News: Evotec präsentiert strategischen Fahrplan für Präzisionsmedizin und bestätigt Ziele des Aktionsplans 2025 auf dem Capital Markets Day
Premier, Inc. to Participate in Upcoming Investor Conferences
Premier, Inc. to Participate in Upcoming Investor Conferences


Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, announced today that members of its management team are scheduled to participate in the following investor

Neue Behandlungsoption für Patienten mit SHPT – Rayaldee® in der Schweiz ab sofort verfügbar
Neue Behandlungsoption für Patienten mit SHPT – Rayaldee® in der Schweiz ab sofort verfügbar


Vifor Pharma Schweiz AG gab heute die Markteinführung des Calcifediol-Retardpräparats Rayaldee® in der Schweiz bekannt. Rayaldee® ist die erste und einzige in Europa zugelassene orale Therapie

DGAP-News: Evotec erweitert molekulare Patientendatenbank mit einzigartiger Nephrologie-Kohorte der Universität Bristol
DGAP-News: Evotec erweitert molekulare Patientendatenbank mit einzigartiger Nephrologie-Kohorte der Universität Bristol
DGAP-News: Evotec erweitert molekulare Patientendatenbank mit einzigartiger Nephrologie-Kohorte der Universität Bristol
DGAP-News: Evotec expands molecular patient database with unique nephrotic syndrome cohort from the University of Bristol
DGAP-News: Evotec expands molecular patient database with unique nephrotic syndrome cohort from the University of Bristol
DGAP-News: Evotec expands molecular patient database with unique nephrotic syndrome cohort from the University of Bristol
Acadia Healthcare Reports Fourth Quarter 2021 Results
Acadia Healthcare Reports Fourth Quarter 2021 Results


Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced financial results for the fourth quarter and year ended December 31, 2021.



Fourth Quarter Highlights




  • Revenue totaled $593.5